Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
297 studies found for:    Inflammatory Myopathies
Show Display Options
Rank Status Study
21 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
22 Completed myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies
Conditions: Polymyositis;   Dermatomyositis
Interventions: Other: transcriptome analysis;   Other: T cell repertoire analysis
23 Completed
Has Results
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Conditions: Myositis;   Dermatomyositis;   Polymyositis;   Juvenile Dermatomyositis
Interventions: Drug: Rituximab;   Drug: Placebo
24 Not yet recruiting Study of Arimoclomol in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
25 Active, not recruiting An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: Bimagrumab;   Drug: Placebo
26 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
27 Terminated Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
Condition: MYOPATHY
Intervention: Biological: hematopoietic stem cell transplantation
28 Unknown  Diagnostic Accuracy of MR in Myositis
Conditions: Myositis;   Muscular Disorders, Atrophic
Intervention: Procedure: Magnetic Resonance Imaging
29 Recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
30 Active, not recruiting Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
31 Completed Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Conditions: Autoimmune/Connective Tissue Diseases;   Idiopathic Inflammatory Myopathies;   IIM
Intervention:
32 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
33 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
34 Completed Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: BYM338/bimagrumab;   Drug: Placebo
35 Recruiting Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Condition: Inclusion Body Myositis (IBM)
Interventions: Drug: Rapamycin;   Drug: Placebo
36 Recruiting Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
Conditions: Rheumatic Diseases;   Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Scleroderma;   Dermatomyositis;   Myositis
Intervention:
37 Recruiting Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD
Condition: Facioscapulohumeral Muscular Dystrophy 1a
Intervention: Other: No intervention, observational
38 Recruiting Environmental Risk Factors for the Anti-synthetase Syndrome
Condition: Myositis
Intervention:
39 Unknown  Rituximab-induced Pulmonary Function Changes
Conditions: Rheumatoid Arthritis;   Inflammatory Myositis
Intervention: Other: Lung function measurement
40 Completed Resistance Exercise Reduces the Expression of Inflammation and Fibrosis Associated Genes in Autoimmune Myositis Patients
Conditions: Myositis;   Exercise
Intervention: Other: exercise

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years